Legal & General Group
MGX icon

Legal & General Group’s Metagenomi Therapeutics MGX Stock Holding History

Legal & General Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,701
Closed -$3.69K – 3565
2025
Q1 		$3.69K Hold
2,701
– – ﹤0.01% 3315
2024
Q4 		$9.75K Buy
2,701
+2,210
+450% +$5.33K ﹤0.01% 3257
2024
Q3 		$1.06K Hold
491
– – ﹤0.01% 3402
2024
Q2 		$2K Sell
491
-9,509
-95% -$65.3K ﹤0.01% 3403
2024
Q1 		$106K Buy
+10,000
New +$115K ﹤0.01% 2735

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group's MGX Position: Q2 2025 in Review

Legal & General Group sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 2,701 shares — an estimated $3.69K sold.

Legal & General Group first reported a position in MGX in Q1 2024 and held it in 5 quarters. The position peaked at $106K in Q1 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Legal & General Group reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 2,701 Metagenomi Therapeutics shares in Q2 2025, an estimated $3.69K.
  • Legal & General Group first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 5 quarters.
  • Legal & General Group's Metagenomi Therapeutics position peaked at $106K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.